Did Bayer and Johnson & Johnson put profit over public safety?
There are currently more than 4,500 Xarelto cases consolidated in federal multidistrict litigation before Judge Eldon E. Fallon in Louisiana under MDL-2592. Lawsuits claim the drug’s makers misrepresented the safety and effectiveness of the drug.
Plaintiffs allege the companies continued to sell Xarelto even when they knew it was dangerous. Plaintiffs also contend that had they known about the severe risks associated with Xarelto, they would not have taken the drug and may have avoided the serious injuries they suffered. Discovery is underway with Defendants and Plaintiffs exchanging information. Many more Xarelto lawsuits have been filed in state courts.
Does Xarelto leave users more vulnerable to internal bleeding?
Bayer and J&J advertise that Xarelto is safe and more convenient than warfarin. In a 2014 report, The Institute for Safe Medicine Practices (ISMP) found that in the first quarter of 2013 alone, nearly 700 people suffered adverse events from Xarelto, including bleeding.
While risk of bleeding exists with all blood thinners, Xarelto is considered more dangerous than most because it does not have a known antidote or reversal agent. Other treatments, including dialysis, have proven to be ineffective for flushing Xarelto out of a patient’s system. While Warfarin, one of the oldest blood thinners on the market, may also cause bleeding, ER doctors can rely on several known antidotes, including vitamin K, to stop a patient’s uncontrolled bleeding.